GO:0002709 regulation of T cell mediated immunity: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002709 (regulation of T cell mediated immunity) describes any biological process that modulates the frequency, rate, or extent of T cell mediated immunity [1,2].
• T cell mediated immunity is controlled at multiple levels, including cytokine signaling, co-inhibitory and co-stimulatory receptors, metabolic fitness, and transcription factor networks [3,4,5].
• Key regulatory molecules include NF-kB-inducing kinase (MAP3K14), TRIM21, PD-1 (PDCD1), TIM-4 (TIMD4), and NOTCH receptors [3,4,5,7].
• Dysregulation of T cell mediated immunity contributes to cancer immune evasion, cytokine release syndrome, and impaired responses in chronic infections such as long COVID-19 [1,2,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of regulatory genes in T cell immunity [3,4,7].
• Understanding this GO term supports development of CAR-T therapies, immune checkpoint blockade, and vaccines targeting T cell memory [1,2,4,5].
Description
T cell mediated immunity is a central arm of adaptive immunity, responsible for eliminating infected or malignant cells. The Gene Ontology term GO:0002709, regulation of T cell mediated immunity, encompasses any process that modulates the frequency, rate, or extent of this response [1,2]. This term is critical for researchers because T cell activity must be tightly controlled to balance effective pathogen clearance against immunopathology. Dysregulation of these regulatory circuits underlies autoimmune diseases, chronic infections, and cancer progression [3,4,8]. Recent studies have identified diverse molecular players that fine-tune T cell responses, including metabolic regulators, ubiquitin ligases, and co-inhibitory receptors [3,4,7]. Understanding GO:0002709 therefore provides a framework for dissecting how immune responses are initiated, sustained, and resolved. This article integrates authoritative QuickGO annotation with real PubMed literature to summarize the mechanisms, key genes, disease relevance, and experimental models associated with regulation of T cell mediated immunity.
regulation of T cell mediated immunity At A Glance
| GO ID | GO:0002709 |
|---|---|
| GO term | regulation of T cell mediated immunity |
| Ontology | biological_process |
| Synonym | regulation of T-cell mediated immunity; regulation of T lymphocyte mediated immunity; regulation of T-lymphocyte mediated immunity |
| Major function | Modulates the frequency, rate, or extent of T cell mediated immunity |
| Related processes | T cell activation, cytokine signaling, immune checkpoint regulation, metabolic fitness |
| Key regulators | MAP3K14, TRIM21, PDCD1, TIMD4, NOTCH receptors |
| Disease relevance | Cancer, cytokine release syndrome, long COVID-19, autoimmunity |
What Is GO:0002709?
According to the Gene Ontology, GO:0002709 (regulation of T cell mediated immunity) is defined as any process that modulates the frequency, rate, or extent of T cell mediated immunity [1,2]. In other words, it includes all molecular and cellular events that control how strongly, how long, and how effectively T cells carry out their immune functions. This regulation can occur at the level of T cell activation, proliferation, differentiation, cytokine production, or cytotoxicity [3,5,8].
Why Is regulation of T cell mediated immunity Important in Cell Biology?
Regulation of T cell mediated immunity is essential for protective immunity and immune homeostasis. Without proper control, T cell responses can be too weak, leading to chronic infections and cancer, or too strong, causing cytokine release syndrome and autoimmune damage [1,2,8]. Understanding GO:0002709 helps researchers identify therapeutic targets for boosting antitumor immunity or dampening pathological inflammation [3,4,5].
• Controls the balance between effective pathogen clearance and immune-mediated tissue damage [1,2].
• Determines the success of cancer immunotherapies such as immune checkpoint blockade and CAR-T cell therapy [1,4,5].
• Regulates T cell memory formation, which is critical for long-term protection against reinfection.
• Influences T helper cell differentiation, affecting responses to tumors and infections.
• Modulates metabolic fitness of T cells, which impacts their persistence and function in tumors.
• Involves ubiquitin-proteasome pathways, such as TRIM21, that can be targeted to enhance T cell activity.
• Dysregulation contributes to cytokine release syndrome, a serious complication of T cell therapies.
• Provides biomarkers and therapeutic targets for chronic viral infections, including long COVID-19.
• Guides development of vaccines that aim to generate robust T cell memory [2,5].
• Offers opportunities for CRISPR-based gene editing to engineer T cells with enhanced or controlled immunity [3,4,7].
What Happens During regulation of T cell mediated immunity?
T cell activation and co-stimulation
In simple terms: T cells need two signals to become fully active: recognition of antigen and additional co-stimulatory signals.
T cell mediated immunity begins with antigen recognition by the T cell receptor (TCR), but full activation requires co-stimulatory signals. Regulatory processes at this stage determine whether T cells become activated or tolerant. For example, TIM-4 provides bimodal regulation of T cell-mediated immune responses, influencing both activation and suppression. NOTCH signaling also modulates T cell activation and differentiation, affecting antitumor immunity.
Cytokine signaling and immune checkpoint control
In simple terms: Cytokines and checkpoint molecules act as brakes or accelerators for T cell responses.
Cytokines such as IL-2 and IFN-gamma promote T cell proliferation and effector function, while immune checkpoint receptors like PD-1 (PDCD1) deliver inhibitory signals. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy, demonstrating that regulation of PD-1 stability is a key control point. NF-kB-inducing kinase (MAP3K14) maintains T cell metabolic fitness in antitumor immunity, linking cytokine signaling to metabolic regulation.
Metabolic regulation of T cell immunity
In simple terms: T cells need energy and building blocks to function; metabolic pathways control their activity.
Metabolic fitness is essential for T cell effector functions. NF-kB-inducing kinase (MAP3K14) maintains T cell metabolic fitness in antitumor immunity, and its loss impairs T cell function. This regulation ensures that T cells have sufficient energy to proliferate and kill target cells. Metabolic checkpoints are therefore integral to GO:0002709.
Differentiation and memory formation
In simple terms: T cells can become different subtypes, and some become memory cells for long-term protection.
Regulation of T cell mediated immunity includes control of T helper cell differentiation. Basu et al. (2021) describe the differentiation and regulation of T(H) cells as a balancing act for cancer immunotherapy. Memory T cell mediated immunity is crucial for long-term COVID-19 protection, and vaccination status affects the quality of this memory. These processes are tightly regulated to ensure appropriate responses upon re-exposure to pathogens.
Termination and resolution of T cell responses
In simple terms: After an infection is cleared, T cell responses must be turned off to prevent damage.
Proper termination of T cell responses is as important as activation. Regulatory mechanisms, including co-inhibitory receptors and apoptosis, contract the T cell population after antigen clearance. Dysregulation of these processes can lead to cytokine release syndrome, as seen in CAR T cell therapy. Understanding how T cell responses are resolved is a key aspect of GO:0002709.
Key Genes Involved in GO:0002709 regulation of T cell mediated immunity
The following genes and proteins are experimentally validated regulators of T cell mediated immunity, as reported in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAP3K14 (NIK) | Maintains T cell metabolic fitness in antitumor immunity | Target for enhancing T cell persistence in cancer |
| TRIM21 | Ubiquitin ligase regulating PD-1 stability | Potentiates immune checkpoint blockade and CAR-T therapy |
| PDCD1 (PD-1) | Inhibitory receptor on T cells | Target of checkpoint inhibitors; regulated by TRIM21 |
| TIMD4 (TIM-4) | Bimodal regulator of T cell responses | Modulates activation and suppression |
| NOTCH1 | Transcription factor regulating T cell differentiation | Influences antitumor immunity and T cell-based therapies |
| NOTCH2 | Transcription factor in T cell development | Modulates T cell-mediated anti-tumor immunity |
| IL2 | T cell growth factor | Promotes T cell proliferation and effector function |
| IFNG | Cytokine enhancing T cell-mediated immunity | Key effector molecule in antitumor and antiviral responses |
| TNF | Pro-inflammatory cytokine | Contributes to cytokine release syndrome |
| IL6 | Cytokine involved in cytokine release syndrome | Target for managing CAR T cell toxicity |
| CD28 | Co-stimulatory receptor | Provides second signal for T cell activation |
| CTLA4 | Inhibitory receptor | Regulates early T cell activation |
| FOXP3 | Regulatory T cell transcription factor | Controls immunosuppression |
| TBX21 (T-bet) | Transcription factor for Th1 differentiation | Promotes cell-mediated immunity |
| GATA3 | Transcription factor for Th2 differentiation | Balances T helper responses |
| RORC (RORgt) | Transcription factor for Th17 differentiation | Involved in inflammatory responses |
| BCL6 | Transcription factor for Tfh differentiation | Supports germinal center responses |
How Is regulation of T cell mediated immunity Regulated?
Regulation of T cell mediated immunity is itself controlled by multiple layers of molecular regulation. NF-kB-inducing kinase (MAP3K14) maintains T cell metabolic fitness, linking metabolic pathways to immune function. The ubiquitin-proteasome system, exemplified by TRIM21, controls the stability of PD-1 and thus the strength of inhibitory signaling. NOTCH signaling provides developmental and activation cues that shape T cell responses. Additionally, cytokine networks, including IL-2 and IFN-gamma, feedback to modulate T cell activity [1,5]. These regulatory mechanisms ensure that T cell responses are appropriately scaled to the threat and resolved after clearance.
regulation of T cell mediated immunity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRIM21 | Cancer immunotherapy resistance | Knockout in CAR T cells to enhance PD-1 degradation |
| MAP3K14 | Impaired antitumor immunity | Knockout or overexpression in T cells to study metabolic fitness |
| PDCD1 | Checkpoint blockade response | Point mutation to stabilize or destabilize PD-1 |
| TIMD4 | Autoimmunity and immune regulation | Knockout mice to assess T cell responses |
| NOTCH1 | T cell-based immunotherapies | Overexpression or knockout in T cells |
Cancer immunotherapy and cytokine release syndrome
Dysregulation of T cell mediated immunity can lead to excessive T cell activation, causing cytokine release syndrome (CRS), a life-threatening complication of CAR T cell therapy. Lee et al. (2019) demonstrated that low molecular weight adapters can regulate CAR T cell-mediated CRS-like toxicity, providing a strategy to control this adverse event. Conversely, enhancing T cell immunity is the goal of immune checkpoint blockade. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy, showing that regulation of PD-1 levels can improve antitumor responses. NF-kB-inducing kinase (MAP3K14) is also critical for maintaining T cell metabolic fitness in antitumor immunity, and its manipulation could boost T cell persistence.
Long COVID-19 and memory T cell responses
Memory T cell mediated immunity plays a key role in long-term protection against COVID-19. Kurmangaliyeva et al. (2025) reported that vaccination status affects memory T-cell mediated immunity in long-term COVID-19, highlighting the importance of regulatory mechanisms that sustain T cell memory. Impaired regulation of T cell responses may contribute to persistent symptoms or inadequate protection.
Autoimmunity and inflammatory disorders
When regulatory mechanisms fail, T cell mediated immunity can attack self-tissues, leading to autoimmune diseases. TIM-4 provides bimodal regulation of T cell-mediated immune responses, and its dysregulation may contribute to autoimmunity. Similarly, imbalances in T helper cell differentiation, as reviewed by Basu et al. (2021), can skew immune responses toward pathological inflammation. Understanding these regulatory pathways is essential for developing therapies for autoimmune and inflammatory conditions.
From regulation of T cell mediated immunity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MAP3K14 regulate T cell metabolic fitness? | Knockout of MAP3K14 in primary T cells or cell lines |
| Does TRIM21-mediated PD-1 degradation enhance CAR T cell function? | Knockout of TRIM21 in CAR T cells |
| What is the role of TIM-4 in T cell activation? | TIMD4 knockout mice or T cell-specific deletion |
| How does NOTCH signaling affect antitumor immunity? | Overexpression or knockdown of NOTCH receptors in T cells |
| Can point mutations in PDCD1 alter checkpoint blockade efficacy? | Knock-in of PDCD1 mutations in T cells |
| Does IL-6 contribute to cytokine release syndrome? | IL6 knockout or overexpression in CAR T cell models |
How to Study the regulation of T cell mediated immunity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality for T cell function | Identify regulators of T cell immunity |
| Flow cytometry | T cell activation, proliferation, cytokine production | Assess T cell responses [1,5] |
| ELISA / cytokine profiling | Cytokine levels (IL-6, IFN-gamma, TNF) | Monitor cytokine release syndrome |
| Seahorse metabolic assay | Glycolysis and oxidative phosphorylation | Measure T cell metabolic fitness |
| RNA-seq | Transcriptional changes in T cells | Identify gene expression programs |
| Western blot / immunoprecipitation | Protein expression and interactions | Study PD-1 regulation by TRIM21 |
| In vivo tumor challenge | Tumor growth and survival | Evaluate antitumor immunity [3,5] |
| CAR T cell cytotoxicity assay | Target cell killing | Assess CAR T cell function [1,4] |
CRISPR screening for regulators of T cell immunity
Genome-wide CRISPR knockout screens can identify genes that regulate T cell mediated immunity. For example, targeting the TRIM21-PD-1 axis was discovered through such approaches. These screens enable unbiased discovery of positive and negative regulators of T cell function.
Flow cytometry and cytokine profiling
Flow cytometry measures T cell activation markers, proliferation, and cytokine production. Cytokine profiling, such as measuring IL-6 and IFN-gamma, is used to assess T cell responses and cytokine release syndrome [1,5].
Metabolic assays
Seahorse extracellular flux analysis and metabolomics can assess T cell metabolic fitness, as demonstrated for MAP3K14. These methods link metabolic regulation to T cell immunity.
In vivo tumor models
Mouse tumor models, including syngeneic and xenograft models, are used to evaluate T cell mediated antitumor immunity. Adoptive transfer of genetically modified T cells allows testing of specific regulatory genes [3,4,5].
How CRISPR Can Be Used to Study GO:0002709 regulation of T cell mediated immunity
Knockout
CRISPR knockout is used to delete genes such as TRIM21, MAP3K14, or PDCD1 to study their roles in T cell mediated immunity. For example, TRIM21 knockout enhances PD-1 degradation and potentiates CAR T cell therapy. MAP3K14 knockout impairs T cell metabolic fitness.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect specific phosphorylation or ubiquitination sites. For instance, point mutations in PDCD1 can alter its stability and interaction with TRIM21. Such models help define precise molecular mechanisms.
Knock-in
Knock-in of reporter genes or tagged proteins allows tracking of T cell regulatory molecules. For example, knocking in a fluorescent tag on PDCD1 enables real-time monitoring of its expression. Knock-in of specific mutations can also model human polymorphisms.
Overexpression
Overexpression of regulatory genes, such as NOTCH1 or TIMD4, can enhance or suppress T cell responses. Overexpression models are useful for gain-of-function studies and for engineering T cells with enhanced antitumor activity [5,7].
How EDITGENE Supports regulation of T cell mediated immunity Research
Researchers studying regulation of T cell mediated immunity-related genes often need to determine whether a candidate gene is causally involved in T cell function. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for regulation of T cell mediated immunity research.
Frequently Asked Questions About regulation of T cell mediated immunity
What is GO:0002709?
GO:0002709 is the Gene Ontology term for regulation of T cell mediated immunity, defined as any process that modulates the frequency, rate, or extent of T cell mediated immunity [1,2].
What genes are involved in regulation of T cell mediated immunity?
Key genes include MAP3K14, TRIM21, PDCD1, TIMD4, NOTCH1, and various cytokines such as IL2 and IFNG [3,4,5,7].
How is T cell mediated immunity regulated?
It is regulated by co-stimulatory and co-inhibitory receptors, cytokine signaling, metabolic pathways, and transcription factors [3,4,5,8].
What diseases are associated with dysregulation of T cell mediated immunity?
Diseases include cancer, cytokine release syndrome, long COVID-19, and autoimmune disorders [1,2,7,8].
How can CRISPR be used to study regulation of T cell mediated immunity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of regulatory genes in T cells [3,4,7].
What is the role of TRIM21 in T cell immunity?
TRIM21 regulates PD-1 stability; targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy.
How does MAP3K14 affect T cell immunity?
MAP3K14 (NF-kB-inducing kinase) maintains T cell metabolic fitness in antitumor immunity.
What is the role of TIM-4 in T cell responses?
TIM-4 provides bimodal regulation of T cell-mediated immune responses, influencing both activation and suppression.
How does NOTCH signaling regulate T cell immunity?
NOTCH signaling modulates T cell differentiation and antitumor immunity, impacting T cell-based immunotherapies.
What methods are used to study regulation of T cell mediated immunity?
Methods include CRISPR screening, flow cytometry, cytokine profiling, metabolic assays, and in vivo tumor models [1,3,4,5].
Conclusion
Regulation of T cell mediated immunity (GO:0002709) is a fundamental biological process that controls the strength, duration, and quality of T cell responses. Dysregulation of this process contributes to cancer, chronic infections, and autoimmunity. Key regulators such as MAP3K14, TRIM21, PD-1, TIM-4, and NOTCH receptors provide promising targets for therapeutic intervention [3,4,5,7]. CRISPR-based models are indispensable for dissecting these mechanisms and for engineering T cells with desired immune properties. EDITGENE offers comprehensive services to support research in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Lee YG et al.. 2019. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.. Nat Commun 10(1):2681 PMID: 31213606
- 2. Kurmangaliyeva SS et al.. 2025. The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.. Iran J Med Sci 50(2):61-68 PMID: 40026299
- 3. Gu M et al.. 2021. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.. Nat Immunol 22(2):193-204 PMID: 33398181
- 4. Shi J et al.. 2025. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy.. Mol Ther 33(3):1073-1090 PMID: 39905727
- 5. Kelliher MA et al.. 2018. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.. Front Immunol 9:1718 PMID: 30967879
- 7. Mizui M et al.. 2008. Bimodal regulation of T cell-mediated immune responses by TIM-4.. Int Immunol 20(5):695-708 PMID: 18367551
- 8. Basu A et al.. 2021. Differentiation and Regulation of T(H) Cells: A Balancing Act for Cancer Immunotherapy.. Front Immunol 12:669474 PMID: 34012451
